After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Arcutis Biotherapeutics Inc is $441.36M. A total of 8.3 million shares were traded on the day, compared to an average of 4.94M shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, ARQT has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 23 BUYs and 34 SELLs from insiders. Insiders purchased 426,138 shares during that period but sold 54,564.
In the most recent transaction, Burnett Patrick sold 1,325 shares of ARQT for 3.54 per share on Jan 02. After the transaction, the insider now owns 57,032 company shares. In a previous transaction on Nov 21, Matsuda Masaru sold 1,850 shares at 1.98 per share. ARQT shares that See Remark owns now total 46,634.
Among the insiders who bought shares, Frazier Life Sciences VIII, L. acquired of 80,000 shares on Oct 24 at a per-share price of $2.50. This resulted in the 10% Owner holding 8,764,232 shares of ARQT after the transaction. In another insider transaction, Burnett Patrick sold 1,605 shares at $7.04 per share on Aug 21. Company shares held by the insider now total 58,357.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, ARQT has a high of $17.57 and a low of $1.76.
As of this writing, ARQT has an earnings estimate of -$0.76 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.43 per share and a lower estimate of -$0.96. The company reported an EPS of -$1.16 in the last quarter, which was 7.20% higher than expectations of -$1.25.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ARQT’s latest balance sheet shows that the firm has $387.06M in Cash & Short Term Investments as of fiscal 2021. There were $77.56M in debt and $33.33M in liabilities at the time. Its Book Value Per Share was $0.76, while its Total Shareholder’s Equity was $297.68M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARQT is Buy with a score of 4.40.
